NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

NeuroDerm is the first to develop liquid levodopa (LD), the gold standard treatment for Parkinson’s disease, thus enabling for the first time continuous sub-cutaneous (SC) administration of this drug. By overcoming its biggest deficiency – short half life – NeuroDerm’s products should transform patients’ lives, offering them clinical benefits that can only be obtained today by undergoing highly invasive surgery.

Latest Updates

NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014

NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014.”> Read More

NeuroDerm Announces Pricing of Initial Public Offering

NeuroDerm Ltd. today announced the pricing of its initial public offering of 4,500,000 ordinary shares. NeuroDerm shares are expected to begin trading on the Nasdaq Global Market on November 14, 2014 under the ticker symbol “NDRM.”> Read More

NeuroDerm Announces Launch of Initial Public Offering

NeuroDerm today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC) > Read More

Our Solutions

NeuroDerm is developing a pipeline of products that address deficiencies in current treatments for the growing population of moderate to severe Parkinson’s disease patients. NeuroDerm is the first to develop a liquid formulation of levodopa/carbidopa (LD/CD). Based on this novel formulation, the company has developed a line of LD/CD products administered through a patch-pump or small belt pump to deliver a continuous, controlled dose of LD/CD. The LD/CD line of products includes: ND0612L for moderate Parkinson’s disease patients, ND0612H for severe Parkinson’s disease patients and ND0680 for the small subset of severe Parkinson’s disease patients whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD.